Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
Abstract
Objective: Eribulin treatment improved overall survival with predictable toxicities in phase 3 trials of patients with previously treated, locally advanced/metastatic breast cancer. This study (NCT02443428) prospectively observed eribulin-treated patients in real-world clinical practice. Methods: This observational multicentre registry study enrolled 76 patients with locally advanced/metastatic breast cancer who had ≤2 prior chemotherapeutic regimens for advanced disease. Eribulin was administered at a 1.23 mg/m<sup>2</sup> dose (days 1 and 8 of every 21-day cycle). Adverse events (AEs) were monitored and effectiveness was assessed per local practice. Results: AEs occurred in 98.7% of patients; 88.2% had eribulin-related AEs. The most common AEs were fatigue (64.5%), alopecia (36.8%), nausea (35.5%) and constipation (30.3%). Serious AEs occurred in 42.1% of patients. The most common grade 3/4 AEs were neutropenia (9.2%), febrile neutropenia (9.2%), dyspnoea (5.3%) and pleural effusion (5.3%). No fatal AEs occurred. Dose reductions occurred in 31.6% of patients, 42.1% experienced dose delays and 9.2% discontinued due to worsening condition. There were complete responses in 2.6% and partial responses in 15.8% of patients. Median time to progression and overall survival were 4.0 and 8.3 months, respectively. Conclusion: Eribulin was well tolerated in real-world clinical practice, comparable to safety and effectiveness reported in other clinical trials.Citation
Kenny L, Beresford M, Brown I, Misra V, Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care (Engl). 2022 Nov 6:e13747. PubMed PMID: 36336468. Epub 2022/11/07. eng.Journal
European Journal of CancerDOI
10.1111/ecc.13747PubMed ID
36336468Additional Links
https://dx.doi.org/10.1111/ecc.13747Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/ecc.13747
Scopus Count
Collections
Related articles
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
- Authors: Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J
- Issue date: 2018 Jun
- Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
- Authors: Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K
- Issue date: 2017 Dec 4
- Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
- Authors: Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH
- Issue date: 2017 Apr
- Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
- Authors: Hayashida T, Jinno H, Mori K, Sato H, Matsui A, Sakurai T, Hattori H, Takayama S, Wada M, Takahashi M, Seki H, Seki T, Nagayama A, Matsumoto A, Kitagawa Y
- Issue date: 2018 Jun 28
- [Efficacy and safety of eribulin for metastatic breast cancer patients].
- Authors: Okishiro M, Egawa C, Kusama H, Matsushita K, Hashimoto N, Kawashima H, Mukai Y, Hamanaka M, Takeno A, Sakisaka H, Nakahira S, Taniguchi H, Suzuki R, Takeda Y, Kato T, Tamura S, Takatsuka Y
- Issue date: 2014 Feb